StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Moderna's price to sales ratio was 44.5× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 2.0× to 44.5×, with a median of 3.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202644.5×+39.4
2025Dec 31, 20255.2×+2.0
2024Dec 31, 20243.2×−1.0
2023Dec 29, 20234.2×+0.9
2022Dec 30, 20223.2×−5.4
2021Dec 31, 20218.7×−159.2
2020Dec 31, 2020167.9×+88.1
2019Dec 31, 201979.7×+74.5
2018Dec 31, 20185.2×–

More Moderna figures

See a number that looks wrong?